Venlafaxine Hydrochloride (Effexor)

A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT.

Also Known As:

Effexor; Efexor; 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl; Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride; Dobupal; Sila-Venlafaxine; Trevilor; Vandral; Venlafaxine; Wy 45030; Wy-45,030; Wy-45030; Hydrochloride, Venlafaxine; Sila Venlafaxine; Wy 45,030; Wy45,030; Wy45030

Networked: 1604 relevant articles (301 outcomes, 383 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Trivedi, Madhukar H: 18 articles (12/2019 - 10/2004)
2.	Thase, Michael E: 17 articles (01/2017 - 09/2005)
3.	Reynolds, Charles F: 11 articles (11/2020 - 01/2002)
4.	Rickels, Karl: 11 articles (05/2019 - 10/2004)
5.	Baldwin, David S: 11 articles (03/2016 - 06/2005)
6.	Loprinzi, Charles L: 11 articles (03/2016 - 11/2002)
7.	Kasper, Siegfried: 10 articles (01/2020 - 01/2002)
8.	Rush, A John: 10 articles (01/2019 - 03/2006)
9.	Ninan, Philip T: 10 articles (01/2014 - 07/2007)
10.	Stein, Dan J: 10 articles (11/2013 - 10/2005)

Related Diseases

1.	Major Depressive Disorder (Major Depressive Disorders) 03/01/2018 - "Elderly patients with major depressive disorder, as defined by DSM-IV, received open-label high-dose, right unilateral ultrabrief pulse ECT, combined with venlafaxine, as part of participating in phase 1 of the National Institute of Mental Health-supported study Prolonging Remission in Depressed Elderly (PRIDE). " 09/01/2010 - "The data from this study indicate that venlafaxine XR is an efficient and safe therapeutic option for patients with major depressive disorder, with the additional effect of reducing associated painful physical symptoms." 04/01/2008 - "The present study indicates that maintenance treatment for 2 years with venlafaxine is cost-effective in patients with recurrent major depressive disorder." 06/21/2000 - "Venlafaxine extended-release (XR) capsules have been shown to be effective in short-term treatment of patients with GAD without major depressive disorder (MDD), but long-term data are needed to establish whether this agent confers persistent benefits. " 06/01/1996 - "The results from this analysis indicate that long-term treatment with venlafaxine in patients with major depressive disorder is effective in maintaining the initial response compared with placebo and suggest that venlafaxine will be effective in the prevention of relapse."
2.	Anxiety Disorders (Anxiety Disorder) 01/01/2004 - "Venlafaxine is an alternative option, beneficial in depression, post-traumatic stress and generalised anxiety disorders. " 01/01/1996 - "Venlafaxine has demonstrated efficacy for depression, and recent reports and clinical experience suggest that it may be effective for the treatment of anxiety disorders as well. " 12/01/2011 - "The current study assessed efficacy of combined cognitive behavioral therapy (CBT) and venlafaxine XR compared to venlafaxine XR alone in the treatment of generalized anxiety disorder (GAD) within settings where medication is typically offered as the treatment for this disorder. " 01/01/2017 - "Although efficacy of venlafaxine extended release (XR) for generalized anxiety disorder (GAD) has been reported in previous analyses in 2002 and 2004, the sample size was rather small and estimate of safety or tolerability was not clear. " 01/01/2013 - "Data collected by this research group assessed the rate of remission after 6 months of treatment of generalized anxiety disorder (GAD) with venlafaxine XR, to search for predictors of remission and to define how early on in treatment later remission can be predicted. "
3.	Pain (Aches) 03/01/2002 - "Venlafaxine (SNaRI), the most investigated of these new drugs, was shown to be effective in the treatment of different kinds of pain, with side-effects profile significantly better than TCAs. " 08/23/2015 - "In the largest study by Rowbotham, 2004, 56% of participants receiving venlafaxine 150 to 225 mg achieved at least a 50% reduction in pain intensity versus 34% of participants in the placebo group and the number needed to treat for an additional beneficial outcome was 4.5. " 07/01/2010 - "Results of Short-Form 36 (SF-36) indicated that patients who received venlafaxine treatment had a significantly greater improvement in body pain and emotional role compared with those who received placebo treatment (P=0.002 and P=0.002, respectively). " 07/01/2009 - "Venlafaxine significantly reduced pain intensity on the BPI and marginally improved self-reported function. " 01/01/2004 - "Pain relief was significantly greater with venlafaxine than with the placebo treatment. "
4.	Depressive Disorder (Melancholia) 04/01/2006 - "Venlafaxine ER was shown to be an effective and safe drug for the treatment of very elderly primary care patients with depressive syndrome and associated anxiety symptoms." 05/01/2009 - "The results achieved show that treatment with venlafaxine extended release significantly improved the clinical condition of climacteric patients with anxiety or depressive disorder. " 01/01/1997 - "Venlafaxine is effective in a broad spectrum of patients, including outpatients and inpatients, those with and without melancholia, patients with symptoms of anxiety or agitation or retardation and patients with first time or recurrent episodes of major depression. " 05/01/2006 - "In this study, venlafaxine extended release shows that it is an effective and safe drug in the treatment of the depressive-anxious symptoms of patients with depressive syndrome treated in primary care, both in remission and response rates. " 06/01/1999 - "The study conducted by Guelfi, in France, in patients presenting with severe depression was designed to evidence the efficacy of venlafaxine in melancholia. "
5.	Neuralgia (Stump Neuralgia) 10/01/2017 - "It is evident that in the majority of studies, when compared with a placebo, there was a clinical significant reduction in neuropathic pain relief when using venlafaxine. " 10/01/2020 - "Meta-analysis and P-curve analysis of the efficacy of venlafaxine versus placebo in the treatment of neuropathic pain." 10/01/2017 - "To investigate the efficacy of venlafaxine for neuropathic pain and review literature to determine if the medication provides adequate neuropathic pain relief. " 06/01/2017 - "Efficacy of Venlafaxine in Neuropathic Pain: A Narrative Review of Optimized Treatment." 01/01/2002 - "The aim of the study was to evaluate the effectiveness of venlafaxine in neuropathic pain. "

Related Drugs and Biologics

1.	Antidepressive Agents (Antidepressants)
2.	Paroxetine (Paxil)
3.	Duloxetine Hydrochloride (Cymbalta)
4.	Serotonin (5 Hydroxytryptamine)
5.	Fluoxetine (Prozac)
6.	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)
7.	Norepinephrine (Noradrenaline)
8.	Gabapentin (Neurontin)
9.	Escitalopram
10.	Sertraline (Zoloft)

Related Therapies and Procedures

1.	Therapeutics
2.	Transcranial Magnetic Stimulation
3.	Drug Therapy (Chemotherapy)
4.	Secondary Prevention
5.	Transcutaneous Electric Nerve Stimulation (TENS)